Furthermore, the literature consistently reports that silencing HSD17B12 can markedly decrease the proliferation and invasion of ovarian and breast cancer cells.[30, 31, 32] A noteworthy addition to this body of evidence is a recent study associating the upregulation of HSD17B12 with poor prognosis and lower event‐free survival rates in neuroblastoma.[43] Indeed, in agreement with these very recent findings, we found that higher HSD17B12 expression is associated with negative prognostic indicators in neuroblastoma. Here, HSD17B12 is linked to breast cancer.